Physician profile
Rabee Korbaj
NPI 1932392073
$1,659.98
in general payments reported to CMS, 2019-2025
25 companies · $530 in 2025
The $530 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $40.92 · 2021: $17.09 · 2022: $115 · 2023: $376 · 2024: $358 · 2025: $530.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,264.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $291.85 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $184.70 | 2019-2020 | |
| Coastal Medical Technologies LLC | $149.43 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $119.12 | 2023 | Rexulti |
| Abbott Laboratories | $113.09 | 2022-2025 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $105.92 | 2019-2025 | Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.20 | 2025 | Caplyta |
| Dexcom, INC. | $81.30 | 2023-2025 | Dexcom G6 Transmitter |
| Boston Scientific Corporation | $69.20 | 2021-2024 | Watchman Access System |
| Gilead Sciences, INC. | $58.32 | 2019-2025 | |
| Amgen INC. | $56.77 | 2022-2024 | Evenity, Prolia, Repatha |
| Novo Nordisk INC | $53.63 | 2024-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $41.77 | 2022-2025 | Airsupra |
| Teva Pharmaceuticals USA, INC. | $33.17 | 2023-2025 | Austedo Xr, Austedo Xr |
| Renalytix Ai, INC. | $32.13 | 2024-2025 | Kidneyintelx Blood Collection Convenience Kit |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Si-Bone, INC. | $24.89 | 2024 | |
| Novartis Pharmaceuticals Corporation | $21.53 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $20.70 | 2025 | Cobenfy |
| Hologic Sales and Service, LLC | $19.82 | 2025 | Thinprep 2000 Processor, Aptima |
| Insmed, INC. | $18.21 | 2024 | Arikayce |
| Actelion Pharmaceuticals US, INC. | $17.40 | 2025 | Uptravi |
| Neurocrine Biosciences, INC. | $15.95 | 2022 | |
| Pfizer INC. | $14.21 | 2023 | |
| Janssen Pharmaceuticals, INC | $13.92 | 2022 | |
| Merck Sharp & Dohme LLC | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rabee Korbaj listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.